Edward Cha

3.4k total citations · 1 hit paper
56 papers, 1.7k citations indexed

About

Edward Cha is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Edward Cha has authored 56 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 15 papers in Immunology. Recurrent topics in Edward Cha's work include Cancer Immunotherapy and Biomarkers (35 papers), Colorectal Cancer Treatments and Studies (11 papers) and Immunotherapy and Immune Responses (11 papers). Edward Cha is often cited by papers focused on Cancer Immunotherapy and Biomarkers (35 papers), Colorectal Cancer Treatments and Studies (11 papers) and Immunotherapy and Immune Responses (11 papers). Edward Cha collaborates with scholars based in United States, South Korea and China. Edward Cha's co-authors include Lawrence Fong, Christian Schindler, Christopher Y. Park, Craig Cummings, Antoni Ribas, Mark Klinger, Yafei Hou, Malek Faham, Jeffrey J. Wallin and Jeffrey R. Infante and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Edward Cha

53 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study

2025 26 citations Sami Mahrus, Colby S. Shemesh et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward Cha United States	21	1.3k	776	425	275	156	56	1.7k
Davis Y. Torrejon United States	10	1.4k 1.1×	924 1.2×	487 1.1×	463 1.7×	230 1.5×	16	2.0k
Malin S. Nilsson Sweden	9	1.4k 1.1×	1.1k 1.4×	306 0.7×	189 0.7×	171 1.1×	17	1.9k
Jesse M. Zaretsky United States	8	1.5k 1.2×	1.3k 1.7×	518 1.2×	278 1.0×	183 1.2×	16	2.1k
Lawrence P. Andrews United States	11	1.3k 1.0×	1.1k 1.5×	392 0.9×	244 0.9×	159 1.0×	14	1.9k
Julian A. Marin‐Acevedo United States	13	1.1k 0.9×	732 0.9×	354 0.8×	358 1.3×	151 1.0×	27	1.7k
Kim C. Ohaegbulam United States	14	1.2k 0.9×	884 1.1×	416 1.0×	339 1.2×	180 1.2×	19	1.8k
Maria Libera Ascierto United States	19	677 0.5×	577 0.7×	397 0.9×	188 0.7×	181 1.2×	44	1.2k
Diwakar Davar United States	20	1.1k 0.9×	810 1.0×	490 1.2×	183 0.7×	105 0.7×	134	1.6k
Spasenija Savic Prince Switzerland	12	1.2k 0.9×	755 1.0×	270 0.6×	410 1.5×	216 1.4×	39	1.6k
Justin D. Saco United States	4	966 0.8×	792 1.0×	368 0.9×	216 0.8×	142 0.9×	5	1.4k

Countries citing papers authored by Edward Cha

Since Specialization

Citations

This map shows the geographic impact of Edward Cha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Cha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Cha more than expected).

Fields of papers citing papers by Edward Cha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Cha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Cha. The network helps show where Edward Cha may publish in the future.

Co-authorship network of co-authors of Edward Cha

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Cha. A scholar is included among the top collaborators of Edward Cha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Cha. Edward Cha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yopp, Adam C., et al.. (2026). Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. Journal of Hepatology.

Chau, Ian, B.C. Cho, M-H. Chen, et al.. (2025). 2094O SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT). Annals of Oncology. 36. S1101–S1102.

Yopp, Adam C., Mingkai Chen, Ann‐Lii Cheng, et al.. (2024). LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Annals of Oncology. 35. S1230–S1230. 35 indexed citations

Jung, Kyung Hae, Seock‐Ah Im, Denise A. Yardley, et al.. (2024). Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease. Cancer Research. 84(9_Supplement). PS12–8. 2 indexed citations

Grippin, Adam, Brian De, Katharina Fink, et al.. (2023). MA15.04 Timing of Pre-Biopsy COVID-mRNA Vaccination and PD-L1 Expression in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 18(11). S153–S154. 1 indexed citations

Hecht, J. Randolph, Steven S. Raman, Arlene Chan, et al.. (2023). Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open. 8(2). 100884–100884. 22 indexed citations

Rudin, Charles M., Andrés Cervantes, Afshin Dowlati, et al.. (2023). Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. ESMO Open. 8(2). 101160–101160. 8 indexed citations

Ko, Andrew H., Kyu‐pyo Kim, Jens T. Siveke, et al.. (2023). Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The Oncologist. 28(6). 553–e472. 37 indexed citations

Patnaik, Amita, Vivek Subbiah, Geoffrey I. Shapiro, et al.. (2021). 513 Trial in progress: phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors in patients with inoperable locally advanced or metastatic solid tumors. SHILAP Revista de lepidopterología. A544–A544.

10.

Blank, Christian U., Deborah J. Wong, Thai H. Ho, et al.. (2021). Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Current Oncology. 28(6). 5466–5479. 6 indexed citations

11.

Sullivan, Ryan J., Omid Hamid, René González, et al.. (2019). Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nature Medicine. 25(6). 929–935. 175 indexed citations

12.

Chau, Ian, Georg Martin Haag, Osama E. Rahma, et al.. (2018). MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types. Annals of Oncology. 29. viii439–viii440. 14 indexed citations

13.

Sullivan, Ryan J., René González, Karl D. Lewis, et al.. (2017). Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAF^V600-mutant metastatic melanoma (mel): Updated safety and clinical activity.. Journal of Clinical Oncology. 35(15_suppl). 3063–3063. 41 indexed citations

14.

Desai, Jayesh, Yong Sang Hong, T.W. Kim, et al.. (2016). Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Annals of Oncology. 27. vi155–vi155. 5 indexed citations

15.

Hwu, Patrick, Omid Hamid, René González, et al.. (2016). Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma. Annals of Oncology. 27. vi380–vi380. 26 indexed citations

16.

Cha, Edward & Lawrence Fong. (2014). Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients. OncoImmunology. 7(4). e956016–e956016. 3 indexed citations

17.

Cha, Edward, Adil Daud, Douglas G. McNeel, Richard Heller, & Lauren Fong. (2011). Systemic immune responses induced by intratumoral plasmid IL-12 electroporation in patients with melanoma.. Journal of Clinical Oncology. 29(15_suppl). 2574–2574. 1 indexed citations

18.

Hoskins, Elizabeth E., Terry Morris, Nicole A. Spardy, et al.. (2008). Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. Oncogene. 28(5). 674–685. 51 indexed citations

19.

Pyun, Hae Wook, et al.. (2007). Concomitant Multiple Revascularizations in Supra-Aortic Arteries: Short-Term Results in 50 Patients. American Journal of Neuroradiology. 28(10). 1895–1901. 20 indexed citations

20.

Park, Christopher Y., et al.. (2000). Immune Response in Stat2 Knockout Mice. Immunity. 13(6). 795–804. 308 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact